Home » Influence. From WHO the recommendations for the composition of the vaccine for the 2023-2024 season

Influence. From WHO the recommendations for the composition of the vaccine for the 2023-2024 season

by admin
Influence.  From WHO the recommendations for the composition of the vaccine for the 2023-2024 season

Periodic updating of influenza vaccine viruses is necessary to ensure vaccine efficacy due to the constant evolution of influenza viruses, including those that circulate and infect humans. WHO has recommended quadrivalent vaccines for use in the 2023-2024 Northern Hemisphere influenza season.

27 FEB

The World Health Organization (WHO) today announced recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season in the Northern Hemisphere. The announcement was made during an information session following a 4-day meeting on the composition of flu vaccines, which is held twice a year.

Periodic updating of influenza vaccine viruses is necessary to ensure vaccine efficacy due to the constant evolution of influenza viruses, including those that circulate and infect humans. WHO recommends that quadrivalent vaccines for use in the 2023-2024 Northern Hemisphere influenza season contain the following elements:

Vaccines obtained in embryonated chicken eggs
– un A/Victoria/4897/2022 (H1N1)pdm09-like virus;
– un virus simile all’A/Darwin/9/2021 (H3N2); e
– a virus similar to B/Austria/1359417/2021 (lineage B/Victoria); And
– a virus similar to B/Phuket/3073/2013 (lineage B/Yamagata).

Vaccines based on cell culture or recombinant

– un virus simile al virus A/Wisconsin/67/2022 (H1N1)pdm09;
– un virus simile al virus A/Darwin/6/2021 (H3N2);
– a virus similar to B/Austria/1359417/2021 (lineage B/Victoria); And
– a virus similar to B/Phuket/3073/2013 (lineage B/Yamagata).

WHO recommends that trivalent vaccines for use in the 2023-2024 influenza season in the Northern Hemisphere contain the following elements:

Vaccines obtained in embryonated chicken eggs
– a virus similar to the A/Victoria/4897/2022 (H1N1)pdm09 virus;
– un virus simile all’A/Darwin/9/2021 (H3N2); e
– a virus similar to B/Austria/1359417/2021 (lineage B/Victoria).

See also  Fitness: endurance training? This is also more efficient

Vaccines based on cell culture or recombinant
– un virus simile al virus A/Wisconsin/67/2022 (H1N1)pdm09;
– un virus simile al virus A/Darwin/6/2021 (H3N2); e
– a virus similar to B/Austria/1359417/2021 (lineage B/Victoria).

February 27, 2023
© breaking latest news


Other articles in Science and Drugs

image_1

image_2

image_3

image_4

image_5

image_6

Quotidianosanità.it

Online newspaper
of health information.

QS Editions srl

P.I. 12298601001

Registered office:
Via Giacomo Peroni, 400
00131 – Roma

Operational headquarters:
Via della Stelletta, 23
00186 – Roma

Site Manager

Luciano Fassari

Editorial director
Francesco Maria Avitto

president
Ernesto Rodriguez

    Joint Venture

  • SICS srl
  • Editions
    Health Communication
    srl

Copyright 2013 © QS Edizioni srl. All rights reserved
– P.I. 12298601001
– registration in the ROC n. 23387
– registration with the Court of Rome n. 115/3013 of 05/22/2013

All rights reserved.
Policy privacy

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy